This is a non-core endpoint: only basic statistics are computed.
In situ neoplasms (controls excluding all cancers)
CD2_INSITU_EXALLC
No definition available.
Endpoint definition
↥individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints
-
Remove individuals based on genotype QC
10509
Control definitions
Extra metadata
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to In situ neoplasms (controls excluding all cancers) based on the number of shared cases.
Broader endpoints:
- In situ neoplasms
- Any event in hilmo or specialist outpatient
- Any ICDMAIN event in hilmo or causes of death
Narrower endpoints:
Summary Statistics
↥Key figures
All | Female | Male | |
---|---|---|---|
Number of individuals | 10509 | 7241 | 3268 |
Unadjusted prevalence (%) | 2.79 | 3.43 | 1.97 |
Mean age at first event (years) | 61.29 | 56.17 | 72.63 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_EXALLC – In situ neoplasms (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after In situ neoplasms (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.